Antimicrobial surveillance: A 20-year history of the SMART approach to addressing global antimicrobial resistance into the future
- PMID: 37866472
- DOI: 10.1016/j.ijantimicag.2023.107014
Antimicrobial surveillance: A 20-year history of the SMART approach to addressing global antimicrobial resistance into the future
Abstract
Antimicrobial resistance (AMR) is a major global public health threat, particularly affecting patients in resource-poor settings. Comprehensive surveillance programmes are essential to reducing the high mortality and morbidity associated with AMR and are integral to informing treatment decisions and guidelines, appraising the effectiveness of intervention strategies, and directing development of new antibacterial agents. Various surveillance programmes exist worldwide, including those administered by government bodies or funded by the pharmaceutical industry. One of the largest and longest running industry-sponsored AMR surveillance programme is the Study for Monitoring Antimicrobial Resistance Trends (SMART), which recently completed its 20th year. The SMART database has grown to almost 500 000 isolates from over 200 sites in more than 60 countries, encompassing all major geographic regions and including many sites in low- and middle-income countries. The SMART surveillance programme has evolved in scope over time, including additional antibacterial agents, pathogens and infection sites, in line with changing epidemiology and medical need. Surveillance data from SMART and similar programmes have been used successfully to detect emerging resistance threats and AMR patterns in specific countries and regions, thus informing national and local clinical treatment guidelines. The SMART database can be accessed readily by physicians and researchers globally, which may be especially valuable to those from countries with limited healthcare resources, where surveillance and resistance data are rarely collected. Continued participation from as many sites as possible worldwide and maintenance of adequate funding are critical factors to fully realising the potential of large-scale AMR surveillance programmes into the future.
Keywords: Antibacterial agents; Antimicrobial resistance; Epidemiology; Global; Gram-negative pathogens.
Copyright © 2023 Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, The Author(s). Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
The challenges and successes of implementing a sustainable antimicrobial resistance surveillance programme in Nepal.BMC Public Health. 2014 Mar 21;14:269. doi: 10.1186/1471-2458-14-269. BMC Public Health. 2014. PMID: 24650008 Free PMC article.
-
Surveillance of antimicrobial resistance in the United Arab Emirates: the early implementation phase.Front Public Health. 2023 Nov 23;11:1247627. doi: 10.3389/fpubh.2023.1247627. eCollection 2023. Front Public Health. 2023. PMID: 38074700 Free PMC article.
-
Review of antimicrobial resistance surveillance programmes in livestock and meat in EU with focus on humans.Clin Microbiol Infect. 2018 Jun;24(6):577-590. doi: 10.1016/j.cmi.2017.09.013. Epub 2017 Sep 29. Clin Microbiol Infect. 2018. PMID: 28970159 Review.
-
Implementation of the World Health Organization Global Antimicrobial Resistance Surveillance System in Uganda, 2015-2020: Mixed-Methods Study Using National Surveillance Data.JMIR Public Health Surveill. 2021 Oct 21;7(10):e29954. doi: 10.2196/29954. JMIR Public Health Surveill. 2021. PMID: 34673531 Free PMC article.
-
Global geographic trends in antimicrobial resistance: the role of international travel.J Travel Med. 2019 Dec 23;26(8):taz036. doi: 10.1093/jtm/taz036. J Travel Med. 2019. PMID: 31115466 Review.
Cited by
-
Broadly reactive monoclonal antibodies against beta-lactamases for immunodetection of bacterial resistance to antibiotics.Sci Rep. 2025 May 30;15(1):19094. doi: 10.1038/s41598-025-04603-2. Sci Rep. 2025. PMID: 40447764 Free PMC article.
-
An Overview of the Recent Advances in Antimicrobial Resistance.Microorganisms. 2024 Sep 21;12(9):1920. doi: 10.3390/microorganisms12091920. Microorganisms. 2024. PMID: 39338594 Free PMC article. Review.
-
Activity of cefepime, carbapenems and new β-lactam/β-lactamase inhibitor combinations on Enterobacter cloacae complex and Klebsiella aerogenes in Spain (SMART 2016-2022).JAC Antimicrob Resist. 2024 Jun 6;6(3):dlae087. doi: 10.1093/jacamr/dlae087. eCollection 2024 Jun. JAC Antimicrob Resist. 2024. PMID: 38847006 Free PMC article.
-
Detection of antimicrobial resistance via state-of-the-art technologies versus conventional methods.Front Microbiol. 2025 Feb 25;16:1549044. doi: 10.3389/fmicb.2025.1549044. eCollection 2025. Front Microbiol. 2025. PMID: 40071214 Free PMC article. Review.
-
Nanomedicines for Pulmonary Drug Delivery: Overcoming Barriers in the Treatment of Respiratory Infections and Lung Cancer.Pharmaceutics. 2024 Dec 11;16(12):1584. doi: 10.3390/pharmaceutics16121584. Pharmaceutics. 2024. PMID: 39771562 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical